U.S. Markets closed
  • S&P 500

    3,443.12
    +16.20 (+0.47%)
     
  • Dow 30

    28,308.79
    +113.39 (+0.40%)
     
  • Nasdaq

    11,516.49
    +37.59 (+0.33%)
     
  • Russell 2000

    1,617.71
    +4.08 (+0.25%)
     
  • Crude Oil

    41.51
    +0.68 (+1.67%)
     
  • Gold

    1,909.40
    -2.30 (-0.12%)
     
  • Silver

    24.75
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1827
    +0.0054 (+0.4613%)
     
  • 10-Yr Bond

    0.7970
    +0.0360 (+4.73%)
     
  • Vix

    29.35
    +0.17 (+0.58%)
     
  • GBP/USD

    1.2945
    +0.0004 (+0.0337%)
     
  • USD/JPY

    105.4610
    +0.0310 (+0.0294%)
     
  • BTC-USD

    11,887.42
    +830.41 (+7.51%)
     
  • CMC Crypto 200

    238.95
    +0.03 (+0.01%)
     
  • FTSE 100

    5,889.22
    +4.57 (+0.08%)
     
  • Nikkei 225

    23,567.04
    -104.06 (-0.44%)
     

How La Jolla (LJPC) Stock Stands Out in a Strong Industry

Zacks Equity Research
·2 mins read

One stock that might be an intriguing choice for investors right now is La Jolla Pharmaceutical Company LJPC. This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. 

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Drugs space as it currently has a Zacks Industry Rank of 25 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there. 

Meanwhile, La Jolla is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term. 

La Jolla Pharmaceutical Company Price and Consensus

La Jolla Pharmaceutical Company Price and Consensus
La Jolla Pharmaceutical Company Price and Consensus

La Jolla Pharmaceutical Company price-consensus-chart | La Jolla Pharmaceutical Company Quote

In fact, over the past month, current quarter estimates have narrowed from a loss of 74 cents per share to a loss of 59 cents per share, while current year estimates have narrowed from a loss of $2.84 per share to a loss of $2.26 per share. This has helped LJPC to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here. 

So, if you are looking for a decent pick in a strong industry, consider La Jolla. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
La Jolla Pharmaceutical Company (LJPC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research